Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Therapeutic Status of Famotidine in COVID-19 Patients: A Review

Sun Apr 14 01:04:05 2024

(2022) Therapeutic Status of Famotidine in COVID-19 Patients: A Review. Infectious Disorders - Drug Targets. pp. 4-11. ISSN 18715265 (ISSN)

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

The novel coronavirus, SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread worldwide. More than 272 million cases of infection have been identified. COVID-19 has affected 223 countries and territories across the world. The principal target of the SARS-CoV-2 infection is the lower respiratory tract. Series of moderate to non-specific severe clinical signs and symptoms appear two to fourteen days after exposure to SARS-CoV-2 in patients with COVID-19 disease, including cough, breath deficiency, and at least two of these symptoms: headache, fever, chills, repeated rigor, myalgia, oropharyngitis, anosmia, and ageusia. No therapeutic agents have been validated to have substantial efficacy in the clinical care of COVID-19 patients in large-scale trials, despite worsening infected rates of COVID-19. Early clinical evidence from many sources suggests that treatment with famotidine may decrease COVID-19-related morbidity and mortality. The mechanism by which famotidine could improve the outcomes of COVID-19 is currently unknown. A more recent postulated mechanism is that the effect of famotidine is mediated by histamine-2 receptor antagonism or inverse agonism, inferring that the SARS-CoV-2, resulting in COVID-19 infection, at least partially leads to the abnormal release of histamine and perhaps dysfunction of mast cells. © 2022 Bentham Science Publishers.

Item Type: Article
Creators:
CreatorsEmail
Mohseni, M.UNSPECIFIED
Raissi, V.UNSPECIFIED
Sharifan, Y.UNSPECIFIED
Barikro, K.UNSPECIFIED
Amiri, S.UNSPECIFIED
Mohseni, M. S.UNSPECIFIED
Raeisi, F.UNSPECIFIED
Masoumi, K.UNSPECIFIED
Khodakarami, S.UNSPECIFIED
Raiesi, O.UNSPECIFIED
Keywords: COVID-19 famotidine histamine-2 receptor antagonism respiratory syndrome disease SARS-coV-2 therapeutic histamine H2 receptor histamine adult respiratory distress syndrome artificial ventilation breathing coronavirus disease 2019 disease severity drug repositioning histamine release hospital mortality human Human respiratory syncytial virus immune response inverse agonism lower respiratory tract respiratory tract disease Review SARS-CoV-2 Alpha SARS-CoV-2 Beta SARS-CoV-2 Gamma SARS-CoV-2 Lambda SARS-CoV-2 Mu Severe acute respiratory syndrome coronavirus 2 drug therapy fever Humans
Divisions:
Page Range: pp. 4-11
Journal or Publication Title: Infectious Disorders - Drug Targets
Journal Index: Scopus
Volume: 22
Number: 3
Identification Number: https://doi.org/10.2174/1871526522666220107125511
ISSN: 18715265 (ISSN)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4125

Actions (login required)

View Item View Item